@article{oai:nagasaki-u.repo.nii.ac.jp:00001897,
 author = {Kato, Takeharu and Itonaga, Hidehiro and Taguchi, Jun and Makiyama, Junya and Fujioka, Machiko and Taguchi, Masataka and Horai, Makiko and Sawayama, Yasushi and Niino, Daisuke and Imaizumi, Yoshitaka and Hata, Tomoko and Yoshida, Shinichiro and Sakamoto, Kana and Takeuchi, Kengo and Ohshima, Koichi and Miyazaki, Yasushi},
 journal = {Leukemia Research Reports},
 month = {Apr},
 note = {A 62-year-old male was diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN) with a MYC rearrangement. Four months after the first unrelated bone marrow transplantation (BMT), he developed the relapsed BPDCN. After the achievement of partial remission following re-induction therapy, he underwent a second BMT from another unrelated donor, and experienced complete remission with grade II acute graft-versus-host disease and moderate chronic graft-versus-host disease. He remains alive in complete remission more than 71 months after the second BMT. These results suggested that donor change at the second transplantation may represent a considerable therapeutic option for patients with relapsed BPDCN., Leukemia Research Reports, 11, pp.31-33; 2019},
 pages = {31--33},
 title = {Successful outcome of second allogeneic bone marrow transplantation for blastic plasmacytoid dendritic cell neoplasm with MYC locus rearrangement},
 volume = {11},
 year = {2019}
}